Clovis Oncology, Inc. (CLVS) Analysts See $-1.71 EPS

October 14, 2018 - By Linda Rogers

Clovis Oncology, Inc. (NASDAQ:CLVS) LogoInvestors sentiment increased to 1.17 in 2018 Q2. Its up 0.12, from 1.05 in 2018Q1. It improved, as 33 investors sold Clovis Oncology, Inc. shares while 48 reduced holdings. 25 funds opened positions while 70 raised stakes. 52.83 million shares or 9.43% more from 48.28 million shares in 2018Q1 were reported.
Piedmont Inv Advsr Limited invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Vanguard has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Pointstate Capital Ltd Partnership owns 3.05M shares for 1.57% of their portfolio. Capital Fund, France-based fund reported 35,524 shares. Federated Pa reported 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Invesco Limited accumulated 343,101 shares. Putnam Invests Llc has invested 0.06% in Clovis Oncology, Inc. (NASDAQ:CLVS). Hudson Bay Cap Mngmt Limited Partnership reported 50,000 shares. Grp One Trading Lp invested 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Wells Fargo Mn holds 0% or 162,286 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,595 shares in its portfolio. Mufg Americas Holdg holds 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 401 shares. Amalgamated Bancorp has 7,283 shares for 0.01% of their portfolio. Amer Group reported 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Essex Investment Mngmt Ltd Liability Company has invested 0.09% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS).

Analysts expect Clovis Oncology, Inc. (NASDAQ:CLVS) to report $-1.71 EPS on November, 7.They anticipate $0.47 EPS change or 37.90 % from last quarter’s $-1.24 EPS. After having $-1.94 EPS previously, Clovis Oncology, Inc.’s analysts see -11.86 % EPS growth. The stock decreased 4.26% or $1.19 during the last trading session, reaching $26.73. About 1.30M shares traded or 15.54% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 53.53% since October 14, 2017 and is downtrending. It has underperformed by 69.15% the S&P500.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Among 2 analysts covering Clovis Oncology (NASDAQ:CLVS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Clovis Oncology had 2 analyst reports since June 10, 2018 according to SRatingsIntel. RBC Capital Markets maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Sunday, June 10. RBC Capital Markets has “Buy” rating and $7300 target.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $1.41 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

More recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: which released: “Clovis Oncology: Some Positives Emerge” on October 03, 2018. Also published the news titled: “Pre-Open Movers 10/02: (DTEA) (OMER) (CLVS) Higher; (SFIX) (NBEV) (VNE) Lower (more…)” on October 02, 2018.‘s news article titled: “Key events next week – healthcare” with publication date: October 12, 2018 was also an interesting one.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: